ArticleOpen forum infectious diseases2025
Epidemiological and Clinical Features of Enterotoxigenic
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- One Health Perspective on the EnterotoxigenicMicroorganisms · 2026Review
- MecVax, an Epitope- and Structure-Based Broadly Protective Subunit Vaccine Against EnterotoxigenicMicroorganisms · 2025Review
- Recent progress in enterotoxigenicInfection and immunity · 2025Review
- Building a Broader Understanding of EnterotoxigenicOpen forum infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Enterotoxigenic Methods: We analyzed data from a cluster-randomized controlled trial of an oral cholera vaccine conducted in an urban slum in Dhaka, Bangladesh. The study covers 90 geographical clusters with an average population of 2988 households/cluster (baseline population 268 896). Two cohort analyses were conducted, 1 as dynamic cohort that included all subjects at vaccination, in-migrants, and births over 4 years and a closed cohort, which included only individuals present at baseline. We evaluated individuals placed under treatment center-based diarrheal surveillance between 2011 and 2015. Results: In the dynamic cohort, the ETEC incidence was 150/100 000 person-years (PY; 95% CI, 141-159), with seasonal peaks during warmer months, and in the closed cohort, the incidence was 153/100 000 PY (95% CI, 140, 166). The highest rate was seen in children aged <1 year (2007; 95% CI, 1664-2402), then in those aged 1-4 years (314; 95% CI, 252-386), and again the rate rose in those aged >45 years (219/100 000 PY; 95% CI, 177-267). The rate of severe ETEC was ≤35/100 000 PY for persons aged ≤45 years (95% CI, 27-44), but rose to 82 for adults aged >45 years (95% CI, 58-113). Conclusions: ETEC diarrhea is a major health problem in young children and older adults, prevention through vaccination and improved water, sanitation, and hygiene should target both age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.